Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WS016 in Patients With Hyperkalemia
NCT07251309Phase 3Recruiting
- Sponsor
- Waterstone Pharmaceuticals
- Start
- Dec 2024
- Primary completion
- Nov 2026
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of WS016 in hyperkalemia (7 arms), sponsored by Waterstone Pharmaceuticals. Primary endpoint: Mean serum potassium level during maintenance phase Days 8-29. Started Dec 2024; status: recruiting.
02
Drugs
WS016
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT07251309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07251309.